针对HER2-阳性乳腺癌患者的创新治疗方法
Beatrice Taurelli Salimbeni1,2, Emanuela Ferraro3, Luca Boscolo Bielo1,4
1Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Via G. Ripamonti 435, 20141, Milan, Italy.
新的疗法和生物标志物正在改善HER2阳性乳腺癌 (BC) 的结果. 整合先进的治疗方法和个性化方法,包括超出HER2状态的新兴生物标志物,是克服耐药性和优化患者护理的关键.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 人类表皮生长因子受体2 (HER2) 过度表达发生在15-20%的乳腺癌 (BC) 中,与更差的预后相关.
- 反HER2单克隆抗体 (mAb) 特拉斯图祖马布通过阻断受体活性和引发免疫反应,改变了HER2阳性BC治疗.
- 随后的进展包括额外的mAbs,氨酸激酶抑制剂 (TKI) 和与化疗结合治疗.
研究的目的:
- 提供对乳腺癌抗HER2疗法近期进展的全面概述.
- 讨论新的方法和未来的组合来克服对当前抗HER2治疗的耐药性.
- 强调以患者为中心的方法和新兴生物标志物的整合的重要性.
主要方法:
- 关于治疗HER2阳性乳腺癌的当前文献的综述.
- 对单克隆抗体 (mAbs) 和氨酸激酶抑制剂 (TKIs) 的进展进行分析.
- 探索新兴生物标志物及其预后/预测意义.
主要成果:
- 正在开发新的疗法和多模式方法来增强抗癌活性.
- 组合策略在克服对传统抗HER2治疗的耐药性方面表现有前途.
- 新兴的生物标志物如PI3K/MAPK通路,PD-L1和TILs可能会改进治疗选择.
结论:
- 对HER2-阳性BC的现代治疗算法需要基于瘤模式和患者因素的个性化治疗.
- 将新兴生物标志物与HER2状态相结合,对于最大限度地提高治疗效益至关重要.
- 未来的战略重点是克服耐药性,并通过先进疗法和生物标志物集成来改善结果.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Mitogens and the Cell Cycle
